Scopus BioPharma Inc.

Feb 10, 2021

Scopus BioPharma Announces Closing of Underwriters' Over-Allotment Option in Full

Feb 08, 2021

Underwriters Exercise Over-Allotment Option in Full, Brings Total Follow-On Public Offering Proceeds to $10.35 Million

Jan 29, 2021

Scopus BioPharma Announces Closing of $9 Million Follow-On Public Offering

Jan 19, 2021

Scopus BioPharma Announces Completion of Clinical Lot Manufacture

Dec 29, 2020

Scopus BioPharma Announces Appointment of Additional Directors

Jun 11, 2020

Scopus BioPharma Licenses Novel Immuno-Oncology Gene Therapy Drug from City of Hope, a Cancer Center in Los Angeles, California